EGFR and non-small cell lung carcinoma: Osimertinib and crizotinib were administered concurrently for an epidermal growth factor receptor (<i>EGFR</i>)-mutated NSCLC developing a <i>MET</i> amplification as a resistance mechanism to osimertinib.